Botulinum toxin as an alternative in the management of neuropathic pain in Guillain Barré syndrome
DOI:
https://doi.org/10.28957/rcmfr.v30n1a9Keywords:
Pain, Guillain Barré Syndrome, Botulinum toxin.Abstract
Pain is a common symptom in Guillain Barré Syndrome, which is present even in pure motor variants and affects quality of life; however, many times in the interdisciplinary management of these patients, pain treatment is left aside. This article reports the case of a young adult diagnosed of Guillain Barré Syndrome, who presents neuropathic pain in the soles of the feet, of high intensity and without response to management with conventional antineuropathic drugs. Botulinum toxin application was performed with significant decrease in pain by analog visual scale and with improvement in quality of life according to SF-26 score and Lattinen Index.References
1. Yuki N, Hartung H-P. Guillain-Barré Syndrome. N Engl J Med. 2012;366:2294-2304. Disponible en: http://doi.org/10.1056/NEJMra1114525.
2. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiol. 2009;32:150-163. Dispo- nible en: http://doi.org/10.1159/000184748.
3. Instituto Nacional de Salud. Dirección de Vigilancia y Análisis del Riesgo en Salud Pública. Boletín Epidemiológico semanal - Semana epidemiológica 05, 27 de enero al 2 de febrero de 2019. Disponible en: https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2019 Boletín epidemiológico semana 5.pdf.
4. Peña L, Moreno CB, Gutiérrez-Álvarez AM. Manejo del dolor en el síndrome de Guillain-Barré. Revisión sistemática. Neurología. 2015;30(7):433-438. Disponible en: https://doi.org/10.1016j.nrl.2014.04.009.
5. Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75(16):1439-1447. Disponible en: http://doi.org/10.1212/wnl.0b013e3181f88345.
6. Rekand T, Gramstad A, Vedeler C. Fatigue, pain and muscle weakness are frequent after Guillain– Barré syndrome and poliomyelitis. J Neurol. 2009;256:349–54. Disponible en: http://doi.org/10.1007/s00415-009-0018-z.
7. Ruts L, van Doorn PA, Lombardi R, Haasdijk ED, Penza P, Tulen JH, et al. Unmyelinated and myelinated skin nerve damage in Guillain- Barré syndrome: correlation with pain and recovery. Pain. 2012;153(2): 399-409. Disponible en: http://doi.org/10.1016/j.pain.2011.10.037.
8. Gorson K, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain–Barré. syndrome. Neurology. 1996;47(3):813-817. Disponi- ble en: http://doi.org/10.1212/wnl.47.3.813.
9 Pan CL, Tseng TJ, Li YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervation in Guillain Barre A syndrome: pathology and clinical correlations. Brain. 2003;126(2):386-397. Disponible en: https://doi.org/10.1093/brain/awg039.
10. Martinez V, Fletcher D, Martin F, Orlikowski D, Sharshar T, Chauvin M, et al. Small fiber impairment predicts neuropathic pain in Guillain–Barré syndrome. Pain. 2010;151(1):53–60. Disponible en: .https://doi.org/10.1016/j.pain.2010.05.017.
11. Luongo L, Sajic M, Grist J, Clark AK, Maione S, Malcangio M. Spinal changes associated with mechanical hypersensitivity in a model of Guillain-Barre´ syndrome. Neurosci Lett. 2008;437:98-102. Disponible en: http://doi.org/http://doi.org/10.1016/j.neulet.2008.04.019.
12. Moale,-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with expe- rimental autoimmune neuritis, an animal model of human inf lammator y demyelinating neuropathy. Brain Behav Immun 2007;21(5):699–710. Disponible en: http://doi.org/10.1016/j.bbi.2006.07.007.
13. Liu J, Wang LN, McNicol ED Pharmacological treatment for pain in Guillain-Barré syndrome (Review). The Cochrane Librar y. 2015, Issue 4. Disponible en: http://doi.org/10.1002/14651858.CD009950.pub2.
14. Chandra K, Neeta B, Garima G, Namita S, Arvind B, Anil A, et al. Gabapentin for the Treatment of Pain in Guillain-Barre´ Syndrome: A Double-Blinded, Placebo-Controlled, Crossover Study, Anesth Analg. 2002;95(6)8:1719–1723. Disponible en: http://doi.org/10.1097/00000539-200212000-00046.
15. Morgenlander JC, Hurwitz BJ, Massey EW. Cabsaicin for the Treatment of Pain in Guillain- Barré Syndrome. Ann Neurol. 1990;28(2):199. Disponible en: https://doi.org/10.1002/ana.410280222.
16. Johnson DS, Dunn MJG. Remifentanil for pain due to Guillain–Barre´ syndrome. Anaesthesia. 2008;63(6):671-681. Disponible en: https://doi.org/10.1111/j.1365-2044.2008.05552.x.
17. Krämer HH, Rolke R, Bickel A, Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. Diab Care. 2004;27(10):2386–2391. Disponible en: http://doi.org/10.2337/diacare.27.10.2386.
18. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diab Care. 2006;29(4):883–887. Disponible en: http: //doi.org/10.2337/diacare.29.04.06.dc05-2180.
19. Lacković Z. New analgesic: Focus on botulinum toxin. Toxicon. 2020;179:1-7. Disponible en: https://doi.org/10.1016/j.toxicon.2020.02.008.
20. Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AD, Luvisetto S, et al. The Analgesic Effect on Neuropathic Pain of Retrogradely Transported botulinum Neurotoxin A Involves Schwann Cells and Astrocytes. PLoS ONE. 2012;7(10): e47977. Disponible en: http://doi.org/10.1371/journal.pone.0047977.
21. Argoff CE. A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain. Clin J Pain. 2002;18(6 Suppl):S177-S181. Disponible en: https://doi.org/10.1097/00002508-200211001-00010.
22. González-Escalada JR, Camba A, Muriel C, Rodríguez M, Contreras D, de Barutell C. Validation of the Lattinen Index for the assessment of chronic pain patients. Rev Soc Esp Dolor. 2012;19(4): 181-188. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462012000400004&lng=es.
2. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiol. 2009;32:150-163. Dispo- nible en: http://doi.org/10.1159/000184748.
3. Instituto Nacional de Salud. Dirección de Vigilancia y Análisis del Riesgo en Salud Pública. Boletín Epidemiológico semanal - Semana epidemiológica 05, 27 de enero al 2 de febrero de 2019. Disponible en: https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2019 Boletín epidemiológico semana 5.pdf.
4. Peña L, Moreno CB, Gutiérrez-Álvarez AM. Manejo del dolor en el síndrome de Guillain-Barré. Revisión sistemática. Neurología. 2015;30(7):433-438. Disponible en: https://doi.org/10.1016j.nrl.2014.04.009.
5. Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, et al. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology. 2010;75(16):1439-1447. Disponible en: http://doi.org/10.1212/wnl.0b013e3181f88345.
6. Rekand T, Gramstad A, Vedeler C. Fatigue, pain and muscle weakness are frequent after Guillain– Barré syndrome and poliomyelitis. J Neurol. 2009;256:349–54. Disponible en: http://doi.org/10.1007/s00415-009-0018-z.
7. Ruts L, van Doorn PA, Lombardi R, Haasdijk ED, Penza P, Tulen JH, et al. Unmyelinated and myelinated skin nerve damage in Guillain- Barré syndrome: correlation with pain and recovery. Pain. 2012;153(2): 399-409. Disponible en: http://doi.org/10.1016/j.pain.2011.10.037.
8. Gorson K, Ropper AH, Muriello MA, Blair R. Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain–Barré. syndrome. Neurology. 1996;47(3):813-817. Disponi- ble en: http://doi.org/10.1212/wnl.47.3.813.
9 Pan CL, Tseng TJ, Li YH, Chiang MC, Lin WM, Hsieh ST. Cutaneous innervation in Guillain Barre A syndrome: pathology and clinical correlations. Brain. 2003;126(2):386-397. Disponible en: https://doi.org/10.1093/brain/awg039.
10. Martinez V, Fletcher D, Martin F, Orlikowski D, Sharshar T, Chauvin M, et al. Small fiber impairment predicts neuropathic pain in Guillain–Barré syndrome. Pain. 2010;151(1):53–60. Disponible en: .https://doi.org/10.1016/j.pain.2010.05.017.
11. Luongo L, Sajic M, Grist J, Clark AK, Maione S, Malcangio M. Spinal changes associated with mechanical hypersensitivity in a model of Guillain-Barre´ syndrome. Neurosci Lett. 2008;437:98-102. Disponible en: http://doi.org/http://doi.org/10.1016/j.neulet.2008.04.019.
12. Moale,-Taylor G, Allbutt HN, Iordanova MD, Tracey DJ. Pain hypersensitivity in rats with expe- rimental autoimmune neuritis, an animal model of human inf lammator y demyelinating neuropathy. Brain Behav Immun 2007;21(5):699–710. Disponible en: http://doi.org/10.1016/j.bbi.2006.07.007.
13. Liu J, Wang LN, McNicol ED Pharmacological treatment for pain in Guillain-Barré syndrome (Review). The Cochrane Librar y. 2015, Issue 4. Disponible en: http://doi.org/10.1002/14651858.CD009950.pub2.
14. Chandra K, Neeta B, Garima G, Namita S, Arvind B, Anil A, et al. Gabapentin for the Treatment of Pain in Guillain-Barre´ Syndrome: A Double-Blinded, Placebo-Controlled, Crossover Study, Anesth Analg. 2002;95(6)8:1719–1723. Disponible en: http://doi.org/10.1097/00000539-200212000-00046.
15. Morgenlander JC, Hurwitz BJ, Massey EW. Cabsaicin for the Treatment of Pain in Guillain- Barré Syndrome. Ann Neurol. 1990;28(2):199. Disponible en: https://doi.org/10.1002/ana.410280222.
16. Johnson DS, Dunn MJG. Remifentanil for pain due to Guillain–Barre´ syndrome. Anaesthesia. 2008;63(6):671-681. Disponible en: https://doi.org/10.1111/j.1365-2044.2008.05552.x.
17. Krämer HH, Rolke R, Bickel A, Birklein F. Thermal thresholds predict painfulness of diabetic neuropathies. Diab Care. 2004;27(10):2386–2391. Disponible en: http://doi.org/10.2337/diacare.27.10.2386.
18. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diab Care. 2006;29(4):883–887. Disponible en: http: //doi.org/10.2337/diacare.29.04.06.dc05-2180.
19. Lacković Z. New analgesic: Focus on botulinum toxin. Toxicon. 2020;179:1-7. Disponible en: https://doi.org/10.1016/j.toxicon.2020.02.008.
20. Marinelli S, Vacca V, Ricordy R, Uggenti C, Tata AD, Luvisetto S, et al. The Analgesic Effect on Neuropathic Pain of Retrogradely Transported botulinum Neurotoxin A Involves Schwann Cells and Astrocytes. PLoS ONE. 2012;7(10): e47977. Disponible en: http://doi.org/10.1371/journal.pone.0047977.
21. Argoff CE. A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain. Clin J Pain. 2002;18(6 Suppl):S177-S181. Disponible en: https://doi.org/10.1097/00002508-200211001-00010.
22. González-Escalada JR, Camba A, Muriel C, Rodríguez M, Contreras D, de Barutell C. Validation of the Lattinen Index for the assessment of chronic pain patients. Rev Soc Esp Dolor. 2012;19(4): 181-188. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1134-80462012000400004&lng=es.
How to Cite
1.
Mancipe García LC, Chaustre Ruiz DM, Rodriguez Mojica YM. Botulinum toxin as an alternative in the management of neuropathic pain in Guillain Barré syndrome. Rev. Colomb. Med. Fis. Rehabil. [Internet]. 2020 Sep. 9 [cited 2024 May 17];30(1):82-8. Available from: https://revistacmfr.org/index.php/rcmfr/article/view/236
Downloads
Download data is not yet available.
Downloads
Additional Files
Published
2020-09-09
Issue
Section
Clinical cases
